The first subjects have been successfully dosed with AX-202 at The Medicines Evaluation Unit in Manchester UK In this phase 1 trial, Arxx Therapeutic’s monoclonal antibody AX-202 is being tested in healthy volunteers and patients with psoriasis, leading into Arxx’s program in systemic sclerosis Oslo, Norway, 8 May 2023 – Arxx Therapeutics, a Norwegian-Danish […]
Oslo, May 18, 2022: The Board of Arxx Therapeutics AS, a biotechnology company pioneering the development of novel therapeutics for fibrotic disease, today announced the appointment of Øystein Soug as CEO, effective today. Øystein Soug comes from Targovax ASA, an Oslo Stock Exchange listed biotechnology company, where he has served as CEO of Targovax since […]
Arxx Therapeutics is sponsoring Scleroderma & Raynaud’s UK's (SRUK) Virtual Conference September 11th 2021. Scleroderma & Raynaud’s UK (SRUK) is the only UK Charity dedicated to improving the lives of people with scleroderma and Raynaud’s phenomenon. The Virtual Conference is lead by world leading medical experts and will be covering a whole range of information […]
Anti-S100A4 monoclonal antibody treatment ameliorates skin fibrosis in inflammatory and noninflammatory pre-clinical models of systemic sclerosis
Funding to support clinical phase 1 readiness
